Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 2, Issue 3, 2000, Pages 175-187

  Fujioka, K ^a   Seaton, T B ^b   Rowe, E ^b   Jelinek, C A ^b   Raskin, P ^c   Lebovitz, H E ^d   Weinstein, S P ^b  

^a SCRIPPS CLINIC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Antiobesity agents; Diet; Norepinephrine; Serotonin; Sibutramine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SIBUTRAMINE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BACKACHE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PAIN; PATIENT COUNSELING; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINUSITIS; SOMNOLENCE; STATISTICAL ANALYSIS; VERTIGO; WEIGHT REDUCTION;

EID: 0034522392     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00081.x     Document Type: Article

References (46)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey. 1988-1994
2. Diabetes in America: Epidemiology and scope of the problem
3. The prevention and treatment of obesity: Application to type 2 diabetes
4. Weight control: Metabolic and cardiovascular effects
5. Long-term effects of modest weight loss in type II diabetic patients
6. Nutrition principles for the management of diabetes and related complications
7. Lifestyle intervention in overweight individuals with a family history of diabetes
8. Diabetic diets and nutritional recommendations: What happens in real life?
9. The comparison of four weight reduction strategies aimed at overweight diabetic patients
10. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence
11. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride
12. Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine
13. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl
14. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus
15. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
16. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study
17. Sibutramine produces dose-related weight loss
18. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
19. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
20. Assessing impact of weight on quality of life
21. An analysis of variance test for normality (complete samples)
22. Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling
23. Average partial association in three-way contingency tables: A review and discussion of alternative tests
24. Tests of glycemia in diabetes
25. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
26. Diet therapy of diabetes: An analysis of failure
27. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women
28. Sibutramine: A review of its contribution to the management of obesity
29. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects
30. The safety and efficacy of a controlled low-energy ('very-low-calorie') diet in the treatment of non-insulin-dependent diabetes and obesity
31. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses
32. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
33. Study 7: Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group
34. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey
35. Hypertrigly-ceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective Study
36. High density lipoproteins in diabetes
37. Relation of glycemic control to diabetic complications and health outcomes
38. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial
39. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
40. A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers
41. Fluoxetine in obese patients with noninsulin-dependent diabetes mellitus
42. Fluoxetine treatment of the obese diabetic
43. Sibutramine in the treatment of overweight non-insulin dependent diabetics
44. Body composition changes following weight loss induced by sibutramine
45. Sibutramine reduces visceral fat, leptin, and estradiol level in obese women
46. Relationship of body fat distribution pattern to atherogenic risk factors in NIDDM: Preliminary results